Warning over DoH drug pricing plan

Prices of branded drugs will be tackled so their cost matches the value they offer to patients, the government has said.

The coalition's ‘programme for government' pledges to ‘reform NICE and move to a system of value-based pricing, so that all patients can access the drugs and treatments their doctors think they need'.

The Conservative party has previously suggested that NICE could be involved in price discussions and that, if treatments are not deemed cost-effective, the NHS would only pay for treatment shown to work in particular patients.

Professor Karol Sikora of pharmaceutical consultancy TranScrip Partners said policies on value-based pricing would need to be considered carefully.

‘It is hard to see how the NHS will be an attractive customer to the global pharmaceutical industry if selling to it requires fulfilling a bureaucratic procurement process,' he said.

Dr Sarah Wilson of the University of Central Lancashire, an expert in the ethics of healthcare provision, said the way value-based pricing was being presented implied decisions about which medicines are available to patients could be made on a case-by-case basis, ignoring the wider economic context.

NICE said it looked forward to seeing the detail of the government's proposals and would happily work with it to ‘secure high quality, good value health and social care'.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus